GlassScriptPhysician profile
Alexander Imas
NPI 1114901444
$33,669.34
in general payments reported to CMS, 2019-2025
40 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 94% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,771 · 2021: $1,075 · 2022: $1,621 · 2023: $13K · 2024: $1,996 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $6,065 · Travel and Lodging: $51.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,418.75 |
| Food and Beverage | $6,064.92 |
| Travel and Lodging | $51.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,207.67 | 2021-2025 | |
| Biodelivery Sciences International, INC. | $11,510.69 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $1,788.01 | 2019-2025 | Belbuca, Nucynta, Xtampza |
| Scilex Pharmaceuticals INC. | $1,226.89 | 2019-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,170.97 | 2019-2025 | Relistor |
| Pfizer INC. | $852.93 | 2019-2025 | |
| Indivior INC. | $662.61 | 2019-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $318.89 | 2019-2020 | |
| Braeburn INC. | $282.77 | 2023-2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $239.42 | 2022-2025 | Quviviq, Quviviq |
| Redhill Biopharma INC. | $227.21 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Orexo US, INC. | $210.73 | 2023-2025 | Zubsolv |
| Zyla Life Sciences, INC. | $209.47 | 2019-2020 | |
| Amgen INC. | $196.31 | 2019-2021 | |
| Lundbeck LLC | $156.96 | 2022-2025 | Vyepti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Imas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.